Rilvegostomig Plus Trastuzumab-Deruxtecan: A Promising Neoadjuvant Therapy in Early-Stage ERBB2-Negative Breast Cancer
The I-SPY2.2 trial evaluated rilvegostomig combined with trastuzumab-deruxtecan in high-risk ERBB2-negative early breast cancer, showing promising pathologic complete response rates in immune-positive tumors while reducing exposure to anthracycline chemotherapy.